News Aureka offers open-source AI module for drug discovery Many AIs used in drug discovery are provided by big tech companies at a cost, but a small US and China-based techbio is taking a different tack.
News AZ pays $200m upfront for Sino Bio COPD drug AstraZeneca has licensed a drug candidate for COPD from China's Sino Bio, which could compete with MSD's Ohtuvayre, in a deal valued at up to $2.1bn.
News Kailera's big obesity reveal puts pressure on shares Fresh from a record-breaking IPO, Kailera revealed keenly anticipated trial results for its oral weight-loss drug, to a mixed reaction.
News Obesity biotech Kalohexis files confidential IPO Just weeks after forming as a spinout from Endevica Bio, obesity drug developer Kalohexis has filed for an IPO.
News Island Pharma drug cleared for Bundibugyo Ebola use Island Pharma has been granted the approvals needed to allow compassionate use of its antiviral galidesivir in the Bundibugyo Ebola outbreak.
News Vertex buys Crinetics for $10bn in endocrinology drive Vertex has made the largest acquisition in its history, agreeing to buy Crinetics in a $10bn deal that adds an approved therapy for acromegaly.
Oncology ASCO 2026: All about DNA damage response, with Luke Piggot Luke Piggot, a principal scientist at Debiopharm, shares some recent data and news about the company's work in DNA damage repair inhibitors.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.